Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company's Integrated Sacral Neuromodulation System for Urinary Urge Incontinence
PR Newswire —
94% of Test-Phase Responders Achieved Significant Symptom Relief with Zero Serious Device-Related Adverse Events New Data Suggests 30 Minutes of Daily iSNM Therapy Provides UUI Symptom Relief SAN JOSE, Calif., March 5, 2026 /PRNewswire/ -- Neuspera® Medical, Inc., the leading developer of...